Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line

被引:0
|
作者
Kohara, H [1 ]
Tabata, M [1 ]
Kiura, K [1 ]
Ueoka, H [1 ]
Kawata, K [1 ]
Chikamori, M [1 ]
Aoe, K [1 ]
Chikamori, K [1 ]
Matsushita, A [1 ]
Harada, M [1 ]
机构
[1] Okayama Univ, Sch Med, Dept Internal Med 2, Okayama 7008558, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
7-ethyl-10-[4-(1-piperidyl)-1-piperidyl] carbonyloxy-camptothecin, a topoisomerase I (topo I) inhibitor, is one of the most active agent against lung cancer, and its radiosensitizing effect has been reported recently. We evaluated a combination in vitro effect of irradiation and 7-ethyl-10-hydroxy-CPT (SN-38), an active metabolite of 7-ethyl-10-[4- (1-piperidyl)-1-piperidyl] carbonyloxy-camptothecin, on a human small cell lung cancer cell line (SBC-3) and its cisplatin-resistant subline (SBC-3/CDDP). Growth-inhibitory effects of irradiation with or without SN-38 were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A modified isobologram method was used to evaluate the treatment interaction. The combination of irradiation and SN-38 showed a synergistic inhibitory effect on the growth of SBC-3/CDDP despite its cross-resistance to irradiation and SN-38. In contrast, the same combination showed only an additive effect on the growth of parental SBC-3 cells. There was no significant difference in topo I protein expression between these two cell lines. In SBC-3 cells, topo I catalytic activity was suppressed by 4 Gy of irradiation, without a decrease of nuclear topo I protein, whereas the exposure of SBC-3 cells to 1 muM SN-38 subsequent to irradiation showed no remarkable additional effects on both topo I activity and protein content. On the other hand, in SBC-3/CDDP cells, topo I activity was unchanged by irradiation, but the subsequent exposure to SN-38 gave rise to a decrease in topo I activity, which was accompanied by a significant decrease in the topo I protein content (P = 0.02). These observations may indicate that SN-38 induces sequestration of topo I onto DNA in radiation-treated SBC-3/CDDP cells and suggest that the synergistic effect of irradiation and SN-38 in SBC-3/CDDP cells was considered attributable to DNA repair-related enhanced recruitment of topo I onto the damaged DNA.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 50 条
  • [21] A synergistic interaction between lapatinib and topoisomerase I inhibitors in cisplatin sensitive and resistant cancer cell lines
    Perry, J.
    Nsubuga, E.
    Joel, S.
    Shamash, J.
    El-Hariry, I.
    Powles, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] CHARACTERIZATION OF A HUMAN SMALL-CELL LUNG-CANCER CELL-LINE RESISTANT TO THE DNA TOPOISOMERASE I-DIRECTED DRUG TOPOTECAN
    SORENSEN, M
    SEHESTED, M
    JENSEN, PB
    BRITISH JOURNAL OF CANCER, 1995, 72 (02) : 399 - 404
  • [23] CYCLOPHOSPHAMIDE, DOXORUBICIN, AND VINCRISTINE IN ETOPOSIDE-RESISTANT AND CISPLATIN-RESISTANT SMALL-CELL LUNG-CANCER
    SHEPHERD, FA
    EVANS, WK
    MACCORMICK, R
    FELD, R
    YAU, JC
    CANCER TREATMENT REPORTS, 1987, 71 (10): : 941 - 944
  • [24] Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP)
    Wang, Qi
    Zhong, Meizuo
    Liu, Wei
    Li, Jianhuang
    Huang, Jin
    Zheng, Le
    EXPERIMENTAL LUNG RESEARCH, 2011, 37 (07) : 427 - 434
  • [25] ESTABLISHMENT AND CHARACTERIZATION OF CISPLATIN-RESISTANT SUBLINES OF HUMAN-LUNG CANCER CELL-LINES
    HONG, WS
    SAIJO, N
    SASAKI, Y
    MINATO, K
    NAKANO, H
    NAKAGAWA, K
    FUJIWARA, Y
    NOMURA, K
    TWENTYMAN, PR
    INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (03) : 462 - 467
  • [26] Proteomic analysis of ubiquitination-associated proteins in a cisplatin-resistant human lung adenocarcinoma cell line
    Qin, Xia
    Chen, Shizhi
    Qiu, Zongyin
    Zhang, Yuan
    Qiu, Feng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 29 (05) : 791 - 800
  • [27] Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells
    Ikuta, K
    Takemura, K
    Kihara, M
    Naito, S
    Lee, E
    Shimizu, E
    Yamauchi, A
    ONCOLOGY REPORTS, 2005, 13 (06) : 1229 - 1234
  • [28] Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xenografts
    Zhang, Linshi
    Zhou, Jiarong
    Yan, Yingcai
    Zhou, Xiaohu
    Zhou, Quan
    Du, Rong
    Hu, Shiqi
    Ge, Wenhao
    Huang, Yu
    Xu, Hao
    Kong, Yang
    Zheng, Huilin
    Ding, Yuan
    Shen, Youqing
    Wang, Weilin
    CANCER LETTERS, 2019, 465 : 36 - 44
  • [29] Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines
    Song, Lin
    Cui, Zhilei
    Guo, Xuejun
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2020, 52 (09) : 944 - 953
  • [30] Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer
    Paul, I.
    Chacko, A. D.
    Stasik, I.
    Busacca, S.
    Crawford, N.
    McCoy, F.
    McTavish, N.
    Wilson, B.
    Barr, M.
    O'Byrne, K. J.
    Longley, D. B.
    Fennell, D. A.
    CELL DEATH & DISEASE, 2012, 3 : e449 - e449